Haematology 2018

Dose effect relationships from clinical data

Endpoint

Assumptions

Source of data

-Mean dose is assumed to be predictive of disease control.

Herbst C et al. Haematologica 2010;95:494–500

Disease recurrence

- HR for 0 vs 20 Gy and HR for 20 vs 30 Gy from randomized trials.

Engert A et al. N Engl J Med 2010;363:6430-5

-A linear interpolation of the HR is performed for mean doses between 0,20 and 30 Gy.

- Doses above 30 Gy assumed not to give benefit

Eich HT et al. J Clin Oncol 2010;28:4199–206.

- Mean dose to heart is assumed predictor of developing

Nimwegen et al 2016

Cardiac related mortality

- Linear ERR: 7.4 %/Gy (male) 7.2%/Gy (female)

- Background mortality as function of age from cdc data - Mean dose to breast is assumed predictor of developing

Second breast cancer

- ERR=14.9%/Gy

- Assumed risk of dying after developing: 10.3% (SEER)

Travis et al 2002

- Mean lung dose is assumed predictor

Second lung cancer

- ERR=14.1%/Gy

- Background risk separate for men and women (SEER)

- Assumed risk of dying after developing: 82.3% (SEER)